ArticleNature communications2025
Poly-β-D-(1,6)-N-acetyl-glucosamine (PNAG) glycan vaccines with broad spectrum neutralizing activities.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The dynamic interplay betweenFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of bacterial vaccines is a complex challenge due to the substantial serological diversity of protective antigens. One promising antigenic target is the conserved surface polysaccharide poly-β-(1,6)-N-acetyl-D-glucosamine (PNAG). Despite its widespread distribution, antibodies raised against PNAG have shown restricted efficacy in promoting microbial elimination in vitro and safeguarding against infections in vivo. Systematic studies and vaccine development have been hindered by limited knowledge of optimal antigenic features, such as chain length and degree of N-acetylation. Here, we describe an effective n + 2 glycosylation strategy enabling controlled synthesis of partially (dPNAG) and fully deacetylated PNAG glycans. Glycan microarray analysis shows that dPNAG glycans with DP8 and DP12 are optimal, with corresponding protein conjugates eliciting the highest IgG titers. Sera containing antibodies against the dPNAG DP8 conjugate with 40% acetylation exhibit the best opsonic activity against three prevalent nosocomial pathogens and confer the highest protection in female BALB/c mice against Staphylococcus aureus, supporting its potential as a vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.